Noble and Aptar launch AdhereITTM for at-home drug delivery

AdhereITTM is an interchangeable, connected add-on that works across a multitude of autoinjector platforms

Noble and Aptar Pharma have launched AdhereITTM, an onboarding product for patients with chronic conditions who use autoinjectors to administer their medications at home.

Adherence to prescribed biologics is a significant challenge. A recent report in the Journal of the American Academy of Dermatology reported that 45% of studied patients suffering from psoriasis discontinue their treatments.

The reasons include insufficient training or time with an instructor, lack of confidence during the self-injection process, and feelings of high anxiety and lack of control. COVID-19 has contributed to the increase utilisation of telemedicine and remote healthcare, which has even further complicated this challenge by reducing healthcare professional (HCP) training opportunities with patients.

AdhereITTM aims to give patients gain control and confidence over their at-home drug delivery while easing the anxiety associated with self-injecting. It integrates with the existing software applications developed by the Digital Healthcare team at Aptar Pharma by pairing a patient’s autoinjector via Bluetooth technology to their mobile phone.

The device, available in two design options to accommodate dexterity for a one-handed or two-handed injection process, detects an injection event and provides visual, audio and haptic feedback about whether the injection was performed correctly.

The AdhereITTM onboarding platform also allows HCPs to monitor their patients’ therapeutic performance via a smart analytical dashboard, providing valuable patient-specific adherence behavior information.

“We are excited to welcome Noble’s AdhereITTM connected onboarding platform into the suite of Aptar Pharma’s Digital Healthcare solutions. This innovative technology further enhances our ability to improve patients’ lives by creating a seamless integration of injectable products into our disease management offerings,” said Adam Shain, Director of Business Development for Digital Healthcare, Aptar Pharma.

“Connected medical devices represent the future of healthcare for patients, pharmaceutical companies, health insurers and HCPs, playing a vital role in the remote tracking and treatment of chronic illnesses, and delivering a range of benefits that include improved drug management, enriched patient experiences and enhanced patient outcomes,” said Tim McLeroy, Noble’s Executive Director of Marketing & Patient Services.